Suppr超能文献

α-突触核蛋白寡聚体在帕金森病中的广泛分布

Widespread Distribution of α-Synuclein Oligomers in -related Parkinson's Disease.

作者信息

Sekiya Hiroaki, Franke Lukas, Hashimoto Yuki, Takata Mariko, Nishida Katsuya, Futamura Naonobu, Hasegawa Kazuko, Kowa Hisatomo, Ross Owen A, McLean Pamela J, Toda Tatsushi, Wszolek Zbigniew K, Dickson Dennis W

机构信息

Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.

Division of Neurology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.

出版信息

bioRxiv. 2024 Dec 20:2024.12.18.629265. doi: 10.1101/2024.12.18.629265.

Abstract

Mutations in leucine-rich repeat kinase 2 () are the most common cause of familial and sporadic Parkinson's disease (PD). While the clinical features of -PD patients resemble those of typical PD, there are significant differences in the pathological findings. The pathological hallmark of definite PD is the presence of α-synuclein (αSYN)-positive Lewy-related pathology; however, approximately half of -PD cases do not have Lewy-related pathology. Lewy-related pathology is a late-stage αSYN aggregation that can be visualized with hematoxylin and eosin stains or conventional immunohistochemistry (IHC). Increasing evidence has indicated that αSYN oligomers, which represent the early-stage of αSYN aggregation, may have neurotoxicity. Visualization of αSYN oligomers requires specialized staining techniques, such as αSYN-proximity ligation assay (PLA). The distribution and severity of αSYN oligomers in the human brain of -PD patients remain unknown. In this study, we performed phosphorylated αSYN-IHC and αSYN-PLA staining on postmortem brain sections of patients with three pathogenic LRRK2 mutants: p.G2019S (n=5), p.I2020T (n=5), and p.R1441C (n=4). The severity of Lewy-related pathology and αSYN oligomers were assessed semi-quantitatively in the brainstem, limbic lobe, basal ganglia, and cerebral cortex. αSYN oligomers were detected in -PD cases even in cases without Lewy-related pathology; a negative correlation was observed between Lewy-related pathology and αSYN oligomers (r=-0.26 [-0.39, -0.12]; P<0.0001). Our findings suggest that αSYN oligomers may represent a common pathological feature of -PD. Notably, patients harboring p.G2019S and p.I2020T had significantly higher levels of αSYN oligomers in those without Lewy-related pathology compared to those with Lewy-related pathology. These cases also had a trend toward shorter disease duration. These results imply that in -PD, αSYN oligomers may initially accumulate in the brain but do not progress to form Lewy-related pathology. The present study suggests that targeting αSYN oligomers may be a therapeutic strategy for -PD even if there is no Lewy-related pathology.

摘要

富含亮氨酸重复激酶2(LRRK2)突变是家族性和散发性帕金森病(PD)最常见的病因。虽然LRRK2-PD患者的临床特征与典型PD患者相似,但病理结果存在显著差异。确诊PD的病理标志是存在α-突触核蛋白(αSYN)阳性的路易体相关病理改变;然而,约一半的LRRK2-PD病例没有路易体相关病理改变。路易体相关病理改变是晚期αSYN聚集,可通过苏木精和伊红染色或传统免疫组织化学(IHC)观察到。越来越多的证据表明,代表αSYN聚集早期阶段的αSYN寡聚体可能具有神经毒性。αSYN寡聚体的可视化需要专门的染色技术,如αSYN邻近连接分析(PLA)。LRRK2-PD患者大脑中αSYN寡聚体的分布和严重程度尚不清楚。在本研究中,我们对三名携带致病性LRRK2突变(p.G2019S,n = 5;p.I2020T,n = 5;p.R1441C,n = 4)患者的死后脑切片进行了磷酸化αSYN-IHC和αSYN-PLA染色。在脑干、边缘叶、基底神经节和大脑皮层中对路易体相关病理改变和αSYN寡聚体的严重程度进行了半定量评估。即使在没有路易体相关病理改变的LRRK2-PD病例中也检测到了αSYN寡聚体;观察到路易体相关病理改变与αSYN寡聚体之间呈负相关(r = -0.26 [-0.39, -0.12];P < 0.0001)。我们的研究结果表明,αSYN寡聚体可能是LRRK2-PD的常见病理特征。值得注意的是,与有路易体相关病理改变的患者相比,携带p.G2019S和p.I2020T的患者在没有路易体相关病理改变的情况下,αSYN寡聚体水平显著更高。这些病例的病程也有缩短的趋势。这些结果表明,在LRRK2-PD中,αSYN寡聚体可能最初在大脑中积累,但不会发展形成路易体相关病理改变。本研究表明,即使没有路易体相关病理改变,靶向αSYN寡聚体可能是LRRK2-PD的一种治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/071b/11702646/5534b1ba70e5/nihpp-2024.12.18.629265v1-f0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验